Visitors Now:
Total Visits:
Total Stories:
Profile image
By Global Market Insights Inc.
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Pulmonary Arterial Hypertension Therapeutics Drugs & Companies Pipeline Review, H2 2016

Monday, October 17, 2016 22:02
% of readers think this story is Fact. Add your two cents.

(Before It's News) adds “Pulmonary Arterial Hypertension -Pipeline Review, H2 2016” new report to its research database. The report spread across 214 pages with table and figures in it.

The Research Report ‘Pulmonary Arterial Hypertension -Pipeline Review, H2 2016′, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Browse full table of contents and data tables at

Analysis of 39 Companies include in this report some of them listed below:

  • Actelion Ltd
  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • AVEO Pharmaceuticals, Inc.
  • Bial -Portela & Ca, S.A.
  • Celsion Corporation
  • Celtaxsys, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • HitGen LTD
  • Insmed Incorporated
  • INVENT Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kowa Company, Ltd.
  • Mast Therapeutics, Inc.
  • Mezzion Pharma Co. Ltd.

Request a sample copy at


-The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
-The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
-The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Enquiry before Buying at  

To receive personalized assistance write to us @ with the report title in the subject line along with your questions or call us at +1 866-764-2150

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.